{"pub_date": "2016-03-12T00:00:00Z", "subsection_name": null, "lead_paragraph": "European regulators have started a review into the safety of Gilead Sciences\u2019 leukemia drug Zydelig over concerns about serious adverse events, including deaths.", "print_page": "2", "document_type": "article", "byline": {"person": [], "original": "By REUTERS", "organization": "REUTERS"}, "multimedia": [], "section_name": "Business Day", "headline": {"content_kicker": "Business Briefing", "print_headline": "Europe Investigates Safety of Gilead Leukemia Drug", "main": "Europe Investigates Safety of Gilead Leukemia Drug"}, "source": "The New York Times", "blog": [], "word_count": "84", "web_url": "http://www.nytimes.com/2016/03/12/business/europe-investigates-safety-of-gilead-leukemia-drug.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "European regulators have started a review into the safety of Gilead Sciences\u2019 leukemia drug Zydelig over concerns about serious adverse events, including deaths.", "_id": "56e360f638f0d81b768a68a3", "abstract": "European regulators announce start of safety review of Gilead Sciences\u2019 leukemia drug Zydelig following rise in number of harmful events reports, including deaths, during three clinical trials.", "keywords": [{"rank": "1", "name": "organizations", "value": "Gilead Sciences Inc", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Leukemia", "is_major": "Y"}, {"rank": "3", "name": "glocations", "value": "Europe", "is_major": "Y"}, {"rank": "4", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y"}, {"rank": "5", "name": "organizations", "value": "European Medicines Agency", "is_major": "N"}, {"rank": "6", "name": "organizations", "value": "Roche Holding AG", "is_major": "N"}]}